{'fraction_non_alphanumeric': 0.03521779425393883, 'fraction_numerical': 0.011121408711770158, 'mean_word_length': 5.708074534161491, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Isoprenaline‐induced changes in activity of the endogenous inhibitor of cAMP‐dependent protein kinases under conditions of β‐adrenoceptor supersensitivity

Isoprenaline‐induced changes in activity of an endogenous, specific inhibitor of cAMP‐dependent protein kinases (type I inhibitor) under conditions of experimental supersensitivity of β‐adrenoceptors were investigated in rat hippocampus and brain stem. Both subchronic administration of reserpine (2.5 mg kg−1, i.p., 4 days, once daily) and i.c.v injections of 6‐hydroxydopamine (250 μg/ventricle, bilaterally, 48 h apart), which are known to increase β‐adrenoceptor sensitivity in the rat brain, markedly enhanced the response of the type I inhibitor activity to isoprenaline. To obtain a significant decrease of type I inhibitor activity in the examined brain structures of these animals, doses of isoprenaline 2–5 times lower than in control groups had to be used. It is suggested that the isoprenaline‐induced decrease of type I inhibitor activity might be used as an index of central β‐adrenoceptor reactivity in‐vivo.